Prevention of influenza in adults and children from the age of 6 months, especially in patients with an increased risk of post-influenza complications. The vaccine should be used in accordance with official recommendations.
Composition:
1 dose (0.5 ml) contains surface antigens of the influenza virus corresponding to the following strains: A (H1N1) - 15 μg HA, A (H3N2) - 15 μg HA and B - 15 μg HA (HA - haemagglutinin). The vaccine complies with the WHO recommendations (for the northern hemisphere) and the EU decision for the current season.
Action:
Influenza vaccine (surface antigen), inactivated. The protective effect is obtained after about 2-3 weeks. Resistance to homologous strains or strains related to virus strains contained in the vaccine is usually maintained for 6 to 12 months after vaccination.
Contraindications:
Hypersensitivity to the active substances, any of the excipients and any ingredient that may be present in trace amounts, such as hen egg residue (ovalbumin, chicken proteins), formaldehyde, trimethylcetylammonium bromide, polysorbate 80 or gentamycin. Disease with fever or acute infection (vaccination should be postponed). Do not give intravascularly.
Precautions:
In patients with congenital or acquired immunodeficiency, the immune response may be insufficient. Safety and efficacy of the vaccine in children below 6 months of age. they have not been determined.
Pregnancy and lactation:
Inactivated influenza vaccines can be given in all periods of pregnancy. A larger set of safety data is available for the second and third trimesters compared to the first trimester; however, data from around the world regarding the use of inactivated influenza vaccines do not indicate any adverse effects on the mother and fetus associated with the vaccine. The vaccine can be used during breastfeeding.
Side effects:
Common: headache, sweating, muscle and joint pain, fever, unwellness, chills, tiredness, local reactions (redness, swelling, pain, bruising, induration). In addition, there may be: transient thrombocytopenia, transient generalized enlargement of the lymph nodes, allergic reactions (in rare cases leading to shock), angioneurotic edema, neuralgia, paresthesia, febrile convulsions, neurological disorders (encephalomyelitis, neuritis, Guillan-Barré syndrome) ), generalized skin reactions (including pruritus, urticaria, non-specific rash), vasculitis connected in very rare cases with transient renal dysfunction.
Dosage:
Intramuscularly or deeply subcutaneously. Adults and children from 36 months: 0.5 ml. Children from the age of 6 months up to 35 months of age: clinical data is limited, a dose of 0.25 ml or 0.5 ml can be given. The dose used should be in accordance with national recommendations. Children who have not been vaccinated before the flu should be given a second dose of vaccine after at least 4 weeks.
(C)
